Enzo Biochem (FRA:EZB) Cash-to-Debt : 8.39 (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Enzo Biochem's cash to debt ratio for the quarter that ended in Jan. 2024 was 8.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Enzo Biochem could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Enzo Biochem's Cash-to-Debt or its related term are showing as below:

FRA:EZB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 4.87 Max: No Debt
Current: 8.39

During the past 13 years, Enzo Biochem's highest Cash to Debt Ratio was No Debt. The lowest was 0.12. And the median was 4.87.

FRA:EZB's Cash-to-Debt is ranked better than
76.21% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.27 vs FRA:EZB: 8.39

Enzo Biochem Cash-to-Debt Historical Data

The historical data trend for Enzo Biochem's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Enzo Biochem Cash-to-Debt Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash-to-Debt

Get a 7-Day Free Trial

13.16

1.46

1.92

2.33

11.77

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															0.27	0.12	11.77	9.85	8.39

Competitive Comparison of Enzo Biochem's Cash-to-Debt

For the Diagnostics & Research subindustry, Enzo Biochem's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzo Biochem's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Cash-to-Debt falls into.

Enzo Biochem Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Enzo Biochem's Cash to Debt Ratio for the fiscal year that ended in Jul. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	74.465	/	(3.226	+	3.1)
	=	11.77

Enzo Biochem's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	55.301	/	(3.821	+	2.771)
	=	8.39

Enzo Biochem (FRA:EZB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Enzo Biochem Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (FRA:EZB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » Cash-to-Debt

Comparable Companies

NOTV VNRX BIOQ STIM PSNL PRE OCX MDXH TTOO XGN TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

ENZ:USA

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines